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Abstract
Introduction
Markers of the systemic inflammatory response, including C-reactive protein and albumin
(combined to form the modified Glasgow Prognostic Score), as well as neutrophil, lympho-
cyte and platelet counts have been shown to be prognostic of survival in patients with can-
cer. The aim of the present study was to examine the prognostic relationship between these
markers of the systemic inflammatory response and all-cause, cancer, cardiovascular and
cerebrovascular mortality in a large incidentally sampled cohort.
Methods
Patients (n = 160 481) who had an incidental blood sample taken between 2000 and 2008
were studied for the prognostic value of C-reactive protein (>10mg/l, albumin (>35mg/l),
neutrophil (>7.5×109/l) lymphocyte and platelet counts. Also, patients (n = 52 091) sampled
following the introduction of high sensitivity C-reactive protein (>3mg/l) measurements
were studied. A combination of these markers, to make cumulative inflammation-based
scores, were investigated.
Results
In all patients (n = 160 481) C-reactive protein (>10mg/l) (HR 2.71, p<0.001), albumin
(>35mg/l) (HR 3.68, p<0.001) and neutrophil counts (HR 2.18, p<0.001) were indepen-
dently predictive of all-cause mortality. These associations were also observed in cancer,
cardiovascular and cerebrovascular mortality before and after the introduction of high sensi-
tivity C-reactive protein measurements (>3mg/l) (n = 52 091). A combination of high sensi-
tivity C-reactive protein (>3mg/l), albumin and neutrophil count predicted all-cause (HR
7.37, p<0.001, AUC 0.723), cancer (HR 9.32, p<0.001, AUC 0.731), cardiovascular (HR
4.03, p<0.001, AUC 0.650) and cerebrovascular (HR 3.10, p<0.001, AUC 0.623) mortality.
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Conclusion
The results of the present study showed that an inflammation-based prognostic score, com-
bining high sensitivity C-reactive protein, albumin and neutrophil count is prognostic of all-
cause mortality.
Introduction
There is now good evidence that markers of the systemic inflammatory response, namely C-re-
active protein and albumin using standard thresholds (termed the Glasgow Prognostic Score,
GPS) have independent prognostic value in patients with a variety of cancers [1]. Similarly,
neutrophils and lymphocytes using standard thresholds (termed the neutrophil lymphocyte
ratio, NLR) have also been shown to have independent prognostic value [2]. Recently, in an
effort to rationalise and consolidate the literature we have examined the relationship between
these markers of the systemic inflammatory response, together with high sensitivity C-reactive
protein measurements and platelet counts, and survival in more than 12,000 cancer patients.
This resulted in an optimised score (termed the optimised Glasgow Prognostic Score, oGPS)
composed of high sensitivity C-reactive protein (>3mg/l), albumin (<35g/l), neutrophil
(>7.5 x 109) and platelet (>400 x 109) counts that had a superior predictive value when com-
pared with the established GPS [3]. It remains to be determined whether such markers and
scores also are associated with survival in other disease states.
It is therefore of interest that there have been numerous reports investigating the relation-
ship between an elevated C-reactive protein concentration and increased risk of cardiovascular
[4–6], cerebrovascular [5,7] and all-cause mortality [8,9]. There have also been occasional re-
ports of other markers of the systemic inflammatory response, including albumin [10,11], neu-
trophil count [12], lymphocyte count [13,14] and platelet count [15] being associated with all-
cause mortality.
Therefore, the aim of the present study was to examine the relationship between markers of
the systemic inflammatory response and all-cause, cancer, cardiovascular and cerebrovascular
mortality, in a large incidental cohort.
Materials and Methods
Study design
From the Glasgow Inflammation Outcome Study (GIOS) cohort previously described, patients
in North Glasgow, who had a single blood sample taken for C-reactive protein and albumin
were considered [16]. Only those patients who also had a differential white cell count available,
including lymphocyte, neutrophil and platelet count were included. Patients were sampled in-
cidentally between January 2000 and October 2008. The sample size was originally based on
similar work investigating the association between C-reactive protein and all-cause survival
[8]. If multiple samples had been taken during this time period, only the initial set was used.
Only those patients undergoing blood sampling after the introduction of the routine measure-
ment of high sensitivity C-reactive protein (1st of August 2006), were included in the analysis
investigating the prognostic value of high sensitivity thresholds (5mg/l). As the presence of
malignancy is known to be associated with activation of the systemic inflammatory response
[16], all patients with a diagnosed malignancy any time prior to or within 14 days of blood
sample were noted and this factor was included in the analysis. Whether the sample was taken
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as an outpatient or inpatient was also noted. All malignancies were included except non-malig-
nant melanoma skin cancers.
Patient outcome and mortality was established through linkage with the Information Ser-
vices Division for Scotland (ISD). Deaths were classed as all-cause and further subdivided into
cancer specific, cardiovascular and cerebrovascular. Patients were excluded if under the age of
16 years, demographic details were incomplete or if returned ISD fields were inaccurate or in-
complete. Ethical approval was granted for the present study by the Research Ethics Commit-
tee, North Glasgow NHS Trust.
Methods
Patients with routine laboratory measurements of C-reactive protein, albumin and a differen-
tial white cell count, including neutrophil, lymphocyte and platelet counts were obtained by
systematically searching the North Glasgow biochemical and haematological database systems.
As previously reported, 223 303 patients were identified [16]. The limit of detection of C-reac-
tive protein was a concentration of less than 5mg/l up to 1st of August 2006 and 0.05mg/l there-
after. Standardised thresholds for C-reactive protein (>10mg/l), neutrophil count (>7.5×109/l),
lymphocyte count (>3×109/l) and platelet count (>400×109/l) were studied. High sensitivity C-
reactive protein threshold>3mg/l, previously reported to be associated with survival [17–20]
and shown to be the optimal threshold in this cohort [3], was also studied. From previously pub-
lished work on the present cohort, cumulative scores based onmarkers of the systemic inflamma-
tory response, were reported to predict cancer outcomes [21]. These scores were simply
composed of variables with similar hazard ratios that had previously been validated in cancer co-
horts, including the mGPS comprising of C-reactive protein and albumin, as well as the addition
of other haematological markers of the systemic inflammatory response including the constitu-
ents of a differential white cell count, in particular the neutrophil count, and a high sensitivity C-
reactive protein measurement. In the present analysis a model was built up in a similar way for
all-cause mortality [3]. Only components that were independently predictive of outcome were
taken forward to be included in the final score. The benefit of using high sensitivity C-reactive
protein measurements was also investigated by substituting the standard threshold (>10mg/L)
with>3mg/L.
Patient outcome and mortality was established through linkage with the ISD for Scotland by
exact matching surname, forename, sex and date of birth. If no match on surname then
Daitch-Mokotoff followed by NYSIIS soundex algorithms were employed. On remaining un-
matched cases, forenames and surnames were switched followed by matching on previous sur-
names, reversing gender, using first initial opposed to full forename and finally on surname
gender and date of birth only. On all those not with exact matches a manual check on whether
to include or exclude was taken. Of the 223 303 patients originally identified, 213 127 were suc-
cessfully matched through the ISD linkage and 10 176 were not identified (5%). Of these
matched patients, 160 481 patients had C-reactive protein and albumin as well as a complete
differential white cell count. The presence of SMR01 records were used to determine whether a
patient was sampled during a hospital admission as well as whether the patient had died. Hos-
pital admission was defined as having been sampled during a continuous inpatient stay.
SMRO6 records containing International Classification of Disease (ICD) codes were used to
identify those with a diagnosis of cancer prior to, or within 14 days of blood sampling, as previ-
ously described [16]. Cancer related mortality was defined as ICD10 codes C00—C97, cardio-
vascular (ischaemic heart disease) related mortality was defined as ICD10 codes I20—I25 and
cerebrovascular disease related mortality was defined as ICD10 codes I60—I69 and established
through ISD. At the time of data collection, the ISD held complete SMR01 data on registered
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deaths until May 2011. Survival was calculated from time of blood sample to date of death or
censor date (31st of May 2011).
The Scottish Index of Multiple Deprivation (SIMD) 2006, as recommended by the ISD on
behalf of NHS Scotland and the Scottish Government Department of Health, was used to mea-
sure deprivation [22]. The SIMD is a validated area-based measure of relative socio-economic
circumstance that uses seven domains (current income; employment; health; education, skills
and training; geographic access to services; housing; and crime) to score small areas (data
zones). Scotland is divided into 6,505 data zones and these have been ranked from 1 (most de-
prived) to 6,505 (least deprived). These have further been divided into quintiles of the Scottish
population; we used quintiles that range from 1 (least deprived) to 5 (most deprived).
Statistics
The relationships between patient demographics and outcome were analysed using the Pear-
son’s chi-square test. Cox proportional hazard model was used to analyse the relationship be-
tween patient demographics, hospital admission, the presence of cancer, C-reactive protein,
albumin, neutrophil, lymphocyte and platelet counts. In those patients with a high sensitivity
C-reactive protein measurement, the prognostic value of the combination of C-reactive pro-
tein, albumin and neutrophils, adjusted for age, sex, deprivation, hospital admission and the
presence of cancer, was analysed using the Cox proportional hazard model and the Area
Under the receiver operating characteristic Curve (AUC). During this analysis the proportion-
ality assumptions in the Cox model were explored using a log minus log visual inspection and
were found to be satisfactory. The relationship between the optimised Glasgow Prognostic
Score and survival was assessed using the Kaplan-Meier log rank. A p value of<0.05 was con-
sidered to have statistical significance in the analysis. Analysis was performed using SPSS soft-
ware (SPSS, Chicago, IL, USA).
Results
From GIOS cohort of 223 303 patients originally described [16], 209 148 (94%) were matched
with a unique patient record in the ISD dataset. Of this group 160 481 fitted the inclusion crite-
ria and had a differential white cell count available, including neutrophil, lymphocyte and
platelet counts. Most patients were under 65 years of age (n = 103 779, 65%) Increasing age re-
sulted in increasing mortality with malignancy being the predominant cause of death in all age
groups (p<0.001). Most patients were female (n = 85 308, 53%) with significantly increased
mortality from cerebrovascular disease (p<0.001) but decreased mortality from malignancy
and ischaemic heart disease (both p<0.001) when compared to males. Forty four percent of pa-
tients (n = 71 156) were SIMD 5 (most deprived) with mortality levels generally increasing
from malignancy, cerebrovascular disease and ischaemic heart disease observed with increasing
deprivation. On follow up of all patients, there were 42 242 deaths in total of which 13 176
(31%) were cancer related, 6076 (14%) were cardiovascular related and 3638 (9%) were cere-
brovascular related. The minimum follow up from blood sample for all patients was 31 months
and the maximum 134 months (median follow up 69 months for survivors). The relationship
between patient demographics, hospital admission, history of cancer, C-reactive protein
(>10mg/l), albumin, neutrophil, lymphocyte and platelet counts and survival (n = 160 481) is
shown in Table 1. Increasing age, male gender, increasing deprivation, hospital admission, his-
tory of cancer, high C-reactive protein (>10mg/l), neutrophil and platelet counts were inde-
pendently associated with an increase in all-cause mortality (all p<0.001). Low albumin and
lymphocyte counts were independently associated with an increase is all-cause mortality (all
p<0.001). Increasing age, male gender, history of cancer, high C-reactive protein (>10mg/l),
Inflammation and Mortality
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neutrophil and platelet counts were independently associated with an increase in cancer specif-
ic mortality (all p<0.001). Low albumin and lymphocytes were independently associated with
an increase in cancer specific mortality (all p<0.001). Increasing age, male gender, increasing
deprivation, hospital admission, history of cancer, high C-reactive protein (>10mg/l), neutro-
phil and platelet counts were independently associated with an increase in cardiovascular
mortality (all p = 0.001). Low albumin was independently associated with an increase in cardio-
vascular mortality (all p<0.001). Increasing age, hospital admission, no history of cancer, high
C-reactive protein (>10mg/l), neutrophil count were independently associated with an in-
crease in cerebrovascular mortality (all p<0.001). Low albumin was independently associated
with an increase in cerebrovascular mortality (all p<0.001).
The relationship between patient demographics, hospital admission, history of cancer, C-re-
active protein (>3mg/l), albumin, neutrophil, lymphocyte and platelet counts and survival in pa-
tients with a differential white cell count following the introduction of high sensitivity C-reactive
protein (n = 52 091) is shown in Table 2. Increasing age, male gender, hospital admission, history
of cancer, high C-reactive protein (>3mg/l), neutrophil and platelet counts were independently
associated with an increase in all-cause mortality (all p<0.001). Low albumin and lymphocyte
counts were independently associated with an increase in all-cause mortality (all p<0.001). In-
creasing age, male gender, history of cancer, high C-reactive protein (>3mg/l), neutrophil and
platelet counts were independently associated with an increase in cancer mortality (all p<0.001).
Low albumin and lymphocyte counts were independently associated with an increase in cancer
mortality (all p<0.001). Increasing age, male gender, hospital admission, history of cancer, high
C-reactive protein (>3mg/l) and neutrophil counts were independently associated with an in-
crease in cardiovascular mortality (all p<0.001). Low albumin was independently associated with
an increase in cardiovascular mortality (p<0.001). Increasing age, hospital admission, history of
cancer, high C-reactive protein (>3mg/l) and neutrophil counts were independently associated
with an increase in cerebrovascular mortality (all p<0.05). Low albumin was independently asso-
ciated with an increase in cerebrovascular mortality (p<0.05).
As C-reactive protein, albumin and neutrophils were consistently predictive of all-cause,
cancer, cardiovascular and cerebrovascular specific mortality, these were taken forward to ex-
amine the prognostic value of their combination. These items were not individually weighted
as they had similar predictive value in multivariate analysis and the focus of this process was to
provide a simple score easily adopted in the clinical setting. The relationship between cumula-
tive markers of the systemic inflammatory response (including high sensitivity C-reactive pro-
tein, albumin and neutrophil count) and mortality (n = 52 091) is shown in Table 3. All
combinations of these systemic inflammatory markers were predictive of all-cause, cancer, car-
diovascular and cerebrovascular specific survival (all p<0.01) independent of age, sex depriva-
tion, hospital admission and the presence of cancer (Fig. 1). The Kaplan-Meier plot, for a score
of 3, shows an initial steep curve that subsequently does not diverge from the curves of a score
of 0–2. This suggests that systemic inflammation is particularly predictive of early all-cause
mortality. The combination of C-reactive protein (>10mg/L), albumin and neutrophil count
had an area under the Receiver Operator Curve (ROC) curve for all-cause mortality of 0.720
(95% CI 0.714–0.727, p<0.001), cancer mortality of 0.728 (95% CI 0.718–0.737, p<0.001), car-
diovascular mortality of 0.645 (95% CI 0.627–0.664, p<0.001) and cerebrovascular mortality
of 0.612 (95% CI 0.589–0.636, p<0.001). The combination of C-reactive protein (>3mg/L), al-
bumin and neutrophil count had an area under the curve for all-cause mortality of 0.723 (95%
CI 0.717–0.729, p<0.001), cancer mortality of 0.731 (95% CI 0.722–0.740, p<0.001), cardio-
vascular mortality of 0.650 (95% CI 0.633–0.668, p<0.001) and cerebrovascular mortality of
0.623 (95% CI 0.599–0.646, p<0.001). The area under the curve represent the full model for
each of the three outcomes.
Inflammation and Mortality
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Discussion
The results of the present study show that, in a large incidentally sampled cohort of patients
(n = 160 481), a number of routinely measured, objective markers of the systemic inflammato-
ry response were independently associated with all-cause mortality. Furthermore, C-reactive
protein, albumin and neutrophils were confirmed to have independent prognostic value in pa-
tients dying of cancer as well as cardiovascular and cerebrovascular disease. These results im-
plicate the activation of the systemic inflammatory response as a key factor in the shortened
survival in common lethal disease states.
The results of the present study are consistent with previous work using individual markers
of the systemic inflammatory response to predict all-cause mortality [8–12] and goes further to
demonstrate that the combination of C-reactive protein, albumin and neutrophils can further
improve the prognostic value of the systemic inflammatory response. Furthermore, these asso-
ciations remained following adjustment for hospital admission and a previous diagnosis of can-
cer, events likely to be associated with raised inflammatory markers and reduced survival. It
was of interest that a history of cancer, in those dying from cardiovascular and cerebrovascular
disease, was positively associated with mortality in univariate survival analysis but negatively
associated in multivariate analysis. The basis of this observation is not clear, however, it is
worth noting that age was a dominant factor associated with outcome, in particular for cardio-
vascular and cerebrovascular mortality. Moreover, when all factors were entered into multivar-
iate analysis, the hazard ratios of a number of variables including C-reactive protein and
albumin, as well as neutrophil, lymphocyte and platelet counts were reduced. Therefore, it may
be that a history of cancer is acting as a surrogate marker for age during univariate analysis
with this effect being corrected for in multivariate regression. A similar interaction may explain
the observed relationship between platelet count and cardiovascular mortality, as it was noted
that as age increased, so did the percentage of patients with a high platelet count (<65 10%,
65–75 12%,>75 13%).
It was also of interest that, for similar incremental increases in individual markers of the sys-
temic inflammatory response, the hazard ratios were greater for cancer mortality, when com-
pared to cardiovascular and cerebrovascular mortality. These results are consistent with those
reported by Marsik and co-workers [8] in a hospital based cohort of 274,515 patients using C-
reactive protein as a marker of the systemic inflammatory response. The basis of this strong
Table 3. The relationship between cumulative markers of the systemic inﬂammatory response (including high sensitivity C-reactive protein) and
mortality in an incidental cohort: Adjusted for age, sex, deprivation, hospital admission and the presence of cancer (n = 52 091).
All-cause mortality Cancer mortality Cardiovascular
mortality
Cerebrovascular
mortality
n (%) Deaths = 8243 Deaths = 3480 Deaths = 929 Deaths = 553
HR p-value AUC HR p-value AUC HR p-value AUC HR p-value AUC
0 26 603 (51) 1
0.720
1
0.728
1
0.645
1
0.612
CRP > 10mg/l 1 13 734 (26) 1.92 <0.001 1.99 <0.001 1.66 <0.001 1.53 <0.001
+Albumin >35g/L 2 8635 (17) 3.45 <0.001 4.27 <0.001 2.67 <0.001 1.76 <0.001
+Neutrophils >7.5×109/l 3 3119 (6) 6.45 <0.001 7.95 <0.001 3.49 <0.001 2.50 <0.001
0 17 542 (34) 1
0.723
1
0.731
1
0.650
1
0.623
hs-CRP >3mg/l 1 19 880 (38) 1.76 <0.001 1.94 <0.001 1.62 <0.001 1.40 0.006
+ Albumin >35g/L 2 11 158 (21) 3.58 <0.001 4.44 <0.001 2.92 <0.001 1.90 <0.001
+ Neutrophils>7.5×109/l 3 3511 (7) 7.37 <0.001 9.32 <0.001 4.03 <0.001 3.10 <0.001
doi:10.1371/journal.pone.0116206.t003
Inflammation and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0116206 March 2, 2015 8 / 12
association between the systemic inflammatory response and cancer mortality, when compared
with cardiovascular and cerebrovascular mortality, is not clear but highlights the potential of
the systemic inflammatory response as a therapeutic oncological target [23,24].
In the present study the variables chosen, and the method of their combination for a cumu-
lative score, was based on previous work establishing the prognostic value of the systemic in-
flammatory response in patients with cancer [3]. It was noted that while the addition of a high
Fig 1. The relationship between cumulative markers of the systemic inflammatory response (including high sensitivity C-reactive protein, albumin
and neutrophil count) and survival in an incidental cohort (0-top, solid line; 1-upper separated dot and dash line, 2-middle large dash line, 3-lower
close dot and dash line, n = 52 091).
doi:10.1371/journal.pone.0116206.g001
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sensitivity C-reactive protein did little to improve the cumulative model's AUC, it did illustrate
the value of a C-reactive protein threshold (<3mg/L) commonly used in cardiovascular disease
and appeared to better differentiate those patients that were likely to do particularly well. The
present Receiver Operator Curve analysis demonstrated relatively wide confidence intervals as
well as overlap between the curves for the different combinations of variables and it is possible
that these do not represent the optimum combination in cardiovascular and cerebrovascular
disease. Nevertheless, the present analysis does produce a functional, easy to use, clinical score
that highlights the importance of the systemic inflammatory response in disease states includ-
ing cancer, cardiovascular and cerebrovascular disease.
The basis of the independent prognostic value of C-reactive protein, albumin and neutrophil
count over all disease states (and platelets in cancer) is likely to be complex. However, these fac-
tors are known to be involved with regulation of the immune/inflammatory response and in par-
ticular the innate immune/inflammatory response. Therefore, it may be hypothesised that the
complementary prognostic value of these factors reflects an upregulation of the innate immune/
inflammatory responses The consistency of observations across different tumour types and now
different disease states suggests that this hypothesis is worthy of further study.
With reference to cancer, the role of markers of the systemic inflammatory response in pre-
dicting outcome has become recognised [1,2] and the clinical utility of combining such markers
with tumour based factors to provide improved patient counselling and personalised treatment
is becoming increasingly recognised [25–27]. The present results provide a framework for the
further development of a paradigm that uses both patient and tumour based objective factors to
predict patient prognosis.
With reference to cardiovascular and cerebrovascular disease, the prognostic value of C-re-
active protein has become increasingly recognised [28]. Indeed, high sensitivity C-reactive pro-
tein has been recommended for use in the risk stratification of cardiovascular disease in certain
patient groups [29]. Therefore, the present results also provide further evidence for the clinical
utility of systemic inflammation-based scoring systems in predicting outcome in cardiovascular
and cerebrovascular disease. Indeed, this approach with C-reactive protein and albumin as
core factors, has recently been validated in the NHANES III cohort [30] and while the AUCs in
the present cohort were around 0.65, this was an improvement on using a single variable alone.
There are striking parallels between the present systemic inflammatory response and the
phenomenon of allopathic (also allostatic) load. This ‘wear and tear’ occurs as a consequence
of the repeated activation of compensatory physiological mechanisms to chronic stress, includ-
ing the hyperactivation of the hypothalamic-pituitary axis [31]. As such, the allostatic load can
significantly accelerate the ageing process with this being proposed as a mechanism by which
deprivation impacts on life expectancy. Therefore, it can be readily envisaged that the systemic
inflammatory response may play a key role in the allostatic load paradigm given that measures
of the systemic inflammatory response were directly associated with increasing levels of depri-
vation in the present study. Indeed, it was recently reported that increased physical activity was
associated with lower inflammatory scores and allostatic load [32]. These associations are wor-
thy of further study.
The present cohort study has a number of limitations. The patients were selected on the
basis that measurements of C-reactive protein, albumin and a differential white cell count had
been performed and were therefore not necessarily representative of all patients treated in the
North Glasgow area. It is also recognised that the Glasgow based population has reduced life
expectancy when compared to the rest of Europe and the present cohort may have had high
levels of concurrent morbidity causing derangement of the variables studied. It is also recog-
nised that while the SIMD has been used in an attempt to control for these confounding fac-
tors, this may not have been fully effective, and there remains the possibility of bias.
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In summary, a number of markers of the systemic inflammatory response, reflecting an op-
timised Glasgow Prognostic Score, have prognostic utility not only in cancer, but also in car-
diovascular and cerebrovascular disease survival. Further work to validate such findings in
other large cohorts is warranted.
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